ad image

I-Mab Biopharma

1 / 1
I-Mab
Announcement

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

I-Mab

PR-10-24-NI-80Nov 07, 2024
AbbVie
Partnership

AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

AbbVie

PR-M09-20-NI-06Sep 04, 2020
WuXi Biologics
Strategic Partnership

I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs

WuXi Biologics

PR-M04-19-NI-065Apr 19, 2019
I-Mab
FDA Approval

I-Mab Receives IND Approval from the US FDA to Initiate Clinical Trials for Its Proprietary TJC4, a Potential Global Best-in-Class Anti-CD47 Monoclonal Antibody

I-Mab

PR-M01-19-NI-082Jan 29, 2019
I-Mab
Immunotherapy

I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy

I-Mab

PR-M11-18-NI-014Nov 05, 2018
ABL Bio
Global Collaboration

ABL Bio and I-Mab Biopharma Announce Global Collaboration on Innovative Bispecific Antibodies

ABL Bio

PR-M08-18-NI-005Aug 01, 2018
I-Mab
Global Collaboration

I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies

I-Mab

PR-M07-18-NI-107Jul 31, 2018
1 / 1